Core B: Pre Clinical Animal Models of PAH The overall goals of the Pre-clinical Core are to provide expertise and novel assessments of pulmonary hypertension and right ventricular function in animal models that support TPPG projects and investigators. The Core will be directed by Dr. Karen Norris, who will lead the development of the non-human primate model of PAH and evaluation of candidate molecules developed in Projects 2 and 3. Dr. Hunter Champion will lead studies involving assessment of PAH in established rodent models utilized in Projects all Projects. The development of a novel, non-human primate model of PH, coupled with the extensive expertise in established mouse and rat models will provide a comprehensive evaluation of mechanistic pathways associated with disease progression. In addition, these models will be utilized by all Projects to evaluate genetic and environmental differences, as well as the effect of candidate small molecules on the progression of PH. Goals of the Core will be accomplished through the following SPECIFIC AIMS:
Aim 1 will provide expertise and novel assessments of pulmonary hypertension and right ventricular function in mouse and rat models of pulmonary hypertension. Model assessments include micro-right heart catheterization, miliar assessments of right ventricular pressure and volume loops, Fulton-index, and exercise capacity. Validated available models include the hypoxia-exposed mouse, the VEGF inhibition mouse model, the monocrotyline exposed rat and mouse, the pulmonary artery banded mouse, and the smoked emphysema mouse with pulmonary hypertension.
In Aim 2 we will further develop and characterize a primate model of pulmonary hypertension secondary to humanized simian immunodeficiency virus infection. The model will be characterized with CT-angiograms, PET/CT, right heart catheterization with assessments of pulmonary artery stiffness and RV pressure-volume function, RV and pulmonary pathology, and molecular characterization of pulmonary vasculature and RV by gene expression analysis. These studies will establish a non-human primate model of HIV- PAH and identify important correlates of disease progression.
Aim 3 will provide a primate model in years 3-10 for pre-clinical trials of candidate small molecule drugs arising from Projects 2 and 3, that require additional safety evaluations prior to phase l-lb human clinical trials

Public Health Relevance

The Pre-clinical Core will provide comprehensive expertise and novel assessments of PAH in pre-clinical models. Additionally, these studies will advance the field with the development and characterization of a novel, non-human primate model of PAH. This new model will complement the advanced physiological and molecular characterization of our existing rodent models and will provide a much needed intermediate step between drug development and clinical application

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL103455-03
Application #
8469904
Study Section
Special Emphasis Panel (ZHL1-CSR-A)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
3
Fiscal Year
2013
Total Cost
$457,999
Indirect Cost
$155,689
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Snyder, Nathaniel W; Golin-Bisello, Franca; Gao, Yang et al. (2015) 15-Oxoeicosatetraenoic acid is a 15-hydroxyprostaglandin dehydrogenase-derived electrophilic mediator of inflammatory signaling pathways. Chem Biol Interact 234:144-53
Simon, Marc A; Lacomis, Christopher D; George, M Patricia et al. (2014) Isolated right ventricular dysfunction in patients with human immunodeficiency virus. J Card Fail 20:414-21
Hill, Michael R; Simon, Marc A; Valdez-Jasso, Daniela et al. (2014) Structural and mechanical adaptations of right ventricle free wall myocardium to pressure overload. Ann Biomed Eng 42:2451-65
Lai, Yen-Chun; Potoka, Karin C; Champion, Hunter C et al. (2014) Pulmonary arterial hypertension: the clinical syndrome. Circ Res 115:115-30
Griffin, Paula J; Sebastiani, Paola; Edward, Heather et al. (2014) The genetics of hemoglobin A2 regulation in sickle cell anemia. Am J Hematol 89:1019-23
Frazziano, Giovanna; Al Ghouleh, Imad; Baust, Jeff et al. (2014) Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4. Am J Physiol Heart Circ Physiol 306:H197-205
Klinke, Anna; Möller, Annika; Pekarova, Michaela et al. (2014) Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. Am J Respir Cell Mol Biol 51:155-62
Sharifi-Sanjani, Maryam; Shoushtari, Ali Hakim; Quiroz, Marisol et al. (2014) Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. J Am Heart Assoc 3:e000670
Fazzari, Marco; Trostchansky, Andrés; Schopfer, Francisco J et al. (2014) Olives and olive oil are sources of electrophilic fatty acid nitroalkenes. PLoS One 9:e84884
Zemke, Anna C; Shiva, Sruti; Burns, Jane L et al. (2014) Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells. Free Radic Biol Med 77:307-16

Showing the most recent 10 out of 47 publications